Suvaxyn Circo Unión Europea - búlgaro - EMA (European Medicines Agency)

suvaxyn circo

zoetis belgium sa - ваксината свинският цирковирус (инактивированных, рекомбинантна) - immunologicals for suidae, inactivated viral vaccines - Свине за угояване) - За активна имунизация на свинете с 3-седмична възраст срещу свинският цирковирус тип 2 (pcv2) за намаляване на вирусния товар в кръвта и от лимфоидни тъкани и фекални избледняват, причинени от инфекция с ЦВС2.

Chf - Bulin 120 g/l solution for injection Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

chf - bulin 120 g/l solution for injection

БУЛ БИО - НЦЗПБ ЕООД - Имуноглобулин Човек Анти-Кримеан Хеморагична Треска - 120 g/l solution for injection

Immunovenin-Intact 50% IgG 50 g/l solution for infusion Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

immunovenin-intact 50% igg 50 g/l solution for infusion

БУЛ БИО - НЦЗПБ ЕООД - Имуноглобулин нормален човек за вътресъдова адм. - 50 g/l solution for infusion

Octagam 10% 100 mg/ml Solution for infusion Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

octagam 10% 100 mg/ml solution for infusion

octapharma (ip) ltd - Имуноглобулин нормален човек за вътресъдова адм. - 100 mg/ml solution for infusion

Hepatect CP 50 IU/ml solution for infusion Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

hepatect cp 50 iu/ml solution for infusion

biotest pharma gmbh - Имуноглобулин нормален човек за вътресъдова адм. - 50 iu/ml solution for infusion

Intratect 50 g/l solution for infusion Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

intratect 50 g/l solution for infusion

biotest pharma gmbh - Имуноглобулин нормален човек за вътресъдова адм. - 50 g/l solution for infusion

Intratect 100 g/l solution for infusion Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

intratect 100 g/l solution for infusion

biotest pharma gmbh - Имуноглобулин нормален човек за вътресъдова адм. - 100 g/l solution for infusion

Gammanorm 165 mg/ml solution for injection Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

gammanorm 165 mg/ml solution for injection

octapharma (ip) limited - Имуноглобулин нормален човек за администриране на внесосудистого - 165 mg/ml solution for injection

Vectormune FP ILT + AE Unión Europea - búlgaro - EMA (European Medicines Agency)

vectormune fp ilt + ae

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - Пиле - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Mhyosphere PCV ID Unión Europea - búlgaro - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - Прасета - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.